
The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform. The company said Tuesday it now provides access to Zepbound, a brand-name version of the drug tirzepatide, as well as to generic liraglutide. Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance, some patients may pay as little as $25, according to a report published by The Wall Street Journal. Other medications for weight loss on the Hims & Hers platform include Ozempic and Wegovy, priced at $1,799 and $1,999 per month, respectively. “We’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,” Hims & Hers said. Lilly said it has no official connection with Hims & Hers. Hims & Hers said it plans to keep expanding its offerings to help people find the treatment that works best for them. “All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond,” Hims & Hers noted. The company’s weight-loss business is growing fast. Hims & Hers expects at least $725 million in revenue from its weight-loss services alone in 2025. … read on > read on >